April 2023
1. CHUNG R, McKiernan J, Arpaia N, Marabelle A, et al
   Neo-Adjuvant immunotherapies: Bladder cancer as a platform for drug development targeting mucosal immunity.
   Eur J Cancer. 2023;187:58-64.
   

   >> Share

   
   November 2022
2. MEYNARD L, Dinart D, Delaunay B, Flechon A, et al
   Chemotherapy following immune checkpoint inhibitors in patients with locally advanced or metastatic urothelial carcinoma.
   Eur J Cancer. 2022;175:43-53.
   

   >> Share

   
   October 2022
3. YOON S, Shin SJ, Kim HC, Kim YS, et al
   Enfortumab vedotin-related pneumonitis is more common than expected and could lead to acute respiratory failure.
   Eur J Cancer. 2022;174:81-89.
   

   >> Share

   
   June 2022
4. LIU Z, Jin K, Zeng H, Shao F, et al
   B7-H4 correlates with clinical outcome and immunotherapeutic benefit in muscle-invasive bladder cancer.
   Eur J Cancer. 2022;171:133-142.
   

   >> Share

   
   May 2022
5. KLUMPER N, Sikic D, Saal J, Buttner T, et al
   C-reactive protein flare predicts response to anti-PD-(L)1 immune checkpoint blockade in metastatic urothelial carcinoma.
   Eur J Cancer. 2022;167:13-22.
   

   >> Share

   
   March 2022
6. SONPAVDE GP, Sternberg CN, Loriot Y, Marabelle A, et al
   Primary results of STRONG: An open-label, multicenter, phase 3b study of fixed-dose durvalumab monotherapy in previously treated patients with urinary tract carcinoma.
   Eur J Cancer. 2022;163:55-65.
   

   >> Share

   
   November 2021
7. SEETHAPATHY H, Street S, Strohbehn I, Lee M, et al
   Immune-related adverse events and kidney function decline in patients with genitourinary cancers treated with immune checkpoint inhibitors.
   Eur J Cancer. 2021;157:50-58.
   

   >> Share

   
   July 2021
8. MORI K, Pradere B, Moschini M, Mostafaei H, et al
   First-line immune-checkpoint inhibitor combination therapy for chemotherapy-eligible patients with metastatic urothelial carcinoma: A systematic review and meta-analysis.
   Eur J Cancer. 2021;151:35-48.
   

   >> Share

   
   
9. BOUDIN L, Patient M, Romeo E, Blade JS, et al
   Lurbinectedin for metastatic small-cell bladder carcinoma.
   Eur J Cancer. 2021;151:1-2.
   

   >> Share

   
   May 2021
10. ROUANNE M, Arpaia N, Marabelle A
    CXCL13 shapes tertiary lymphoid structures and promotes response to immunotherapy in bladder cancer.
    Eur J Cancer. 2021 May 7. pii: S0959-8049(21)00222.
    

    >> Share

    
    March 2021
11. GROENEVELD CS, Fontugne J, Cabel L, Bernard-Pierrot I, et al
    Tertiary lymphoid structures marker CXCL13 is associated with better survival for patients with advanced-stage bladder cancer treated with immunotherapy.
    Eur J Cancer. 2021;148:181-189.
    

    >> Share

    
    
12. BAART VM, van der Horst G, Deken MM, Bhairosingh SS, et al
    A multimodal molecular imaging approach targeting urokinase plasminogen activator receptor for the diagnosis, resection and surveillance of urothelial cell carcinoma.
    Eur J Cancer. 2021;146:11-20.
    

    >> Share

    
    May 2020
13. MATSUMOTO S, Kijima T, Matsuoka Y, Yamamoto M, et al
    A case of recurrent thrombocytopenia involving divergent immune-related mechanisms associated with pembrolizumab.
    Eur J Cancer. 2020;131:104-107.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share